期刊文献+

乙型脑炎减毒活疫苗生产用地鼠易感病毒ELISA检测方法的优化及验证

Optimization and validation of enzyme linked immunosorbent assay for hamster-susceptible viruses used for production of live attenuated Japanese encephalitis vaccine
原文传递
导出
摘要 目的对乙型脑炎减毒活疫苗生产用地鼠易感病毒ELISA检测方法进行优化,并对该方法进行验证。方法将ELISA方法进行优化后,检测地鼠血清中的呼肠孤病毒3型(reovirus 3,Reo3)、小鼠肺炎病毒(pneumonia virus of mice,PVM)、仙台病毒(Sendai virus,SV)和淋巴细胞脉络丛脑膜炎病毒(lymphocytic choriomeningitis virus,LCMV),验证该方法的重复性、中间精密性及特异性,并根据WHO/VSQ/97.02的要求,制定验证参数的可接受标准。结果优化后的ELISA方法具有良好的重复性、中间精密性及特异性,各项验证参数均达到预先设定的可接受标准。结论该方法可用于乙型脑炎减毒活疫苗的质量控制。 Objective To optimize and validate the enzyme linked immunosorbent assay(ELISA)for hamster-susceptible viruses used for production of live attenuated Japanese encephalitis(JE) vaccine.Methods The ELISA was optimized,and used for determination of the reovirus 3(Reo3),pneumonia virus of mice(PVM),Sendai virus(SV)and lymphocytic choriomeningitis virus(LCMV) in sera of hamster to validate the reproducibility,intermediate precison and specificity,based on which the acceptable criteria for validation parameters was established according to the requirements in WHO /VSQ / 97.02.Results The optimized ELISA showed high reproducibility,intermediate precison and specificity,of which the various validation parameters met the designed acceptable criteria.Conclusion The optimized ELISA may be used for the quality control of live attenuated JE vaccine.
出处 《中国生物制品学杂志》 CAS CSCD 2015年第11期1214-1218,共5页 Chinese Journal of Biologicals
关键词 乙型脑炎减毒活疫苗 酶联免疫吸附试验 优化 验证 Live attenuated Japanese encephalitis vaccine Enzyme linked immunosorbent assay(ELISA) Optimization Verification
  • 相关文献

参考文献9

  • 1何维,曹雪涛,熊思东,等.医学免疫学[M].2版.北京:人民卫生出版社,2010:370-373.
  • 2World Health Organization.Annex 2.WHO good practices for active pharmaceutical ingredients,section 12.8:validation of analytical methods[J].WHO Technical Report Series,2010,957:167.
  • 3中华人民共和国卫生部.药品生产质量管理规范附录[S].2011-01-17.
  • 4World Health Organization.Annex 4.Supplementary guidelines on good manufacturing practices:validation;Appendix 4Analytical method validation[R].WHO Technical Report Series,2006,937:148-152.
  • 5World Health Organization.Annex 1.WHO good practices for pharmaceutical quality control laboratories[R].WHO Technical Report Series,2010,957:81-129.
  • 6World Health Organization.Supplementary guidelines on good manufacturing practices(GMP):Validation;Annex 4,Analytical method validation.Working document QAS/03.055/Rev.2[EB/OL](2010-04-22)[2015-01-06].http://www.who.int/medicines/areas/quality_safety/quality_assurance/Supple mentary GMPV-alidation TRS937 Annex4.pdf.
  • 7ICH Harmonised tripartite guideline.Q2(R1):Validation of analytical procedures:text and methodology[EB/OL](2010-04-22)[2015-01-06].http://www.fda.gov/Drugs/Guidance Compliance-Regulatory Informa-tion/Guidances/ucm265700.htm.
  • 8Chaloner-Larsson G,Anderson R,Egan A.A WHO guide to good manufacturing practices(GMP)requirements:Part 2:Validation[S].WHO Global Programme for Vaccines and Immunization,CH-1211 Geneva 27,Switzerland.2010:65-69.
  • 9Krause SO.Methods for biopharmaceutical-a guide for riskbased validation and implementation strategies[M].United States:PDA&DHI Publishing,LLC,2007:40-60.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部